Themis announced the close of a Series C financing round led by Global Health Investment Fund (GHIF) as a new investor in the company. Glenn Rockman, Partner at GHIF, will join Themis’ Supervisory Board. The Series C proceeds will be used to advance Themis’ clinical and pre-clinical vaccine development programs.
by eazee-designstudio
Today, Ambu A/S – a leader in the development, manufacture and marketing of single-use devices for hospitals – has agreed to acquire invendo medical GmbH for a purchase price of up to EUR 225m. invendo medical is a leading developer of sterile, single-use HD endoscopy products in the field of gastroenterology and gastrointestinal surgery.
Immatics today announced the completion of its Series E financing, raising $58 million.
Immatics today announced that it has initiated enrollment of patients into a Phase I trial of IMA201, its first T-cell Receptor (TCR)-transduced adoptive cell therapy program.
MSD today announced the acquisition of Rigontec for up to US$553M
The further development of a promising Chikungunya vaccine candidate by Themis Bioscience is now supported with 3 Mio. GBP by the United Kingdom's innovation agency, Innovate UK. Themis will use these funds to identify and validate a correlate of protection for its prophylactic Chikungunya vaccination candidate.
Immatics today announced that it has initiated enrolment of patients into a phase I trial of its first adoptive cellular therapy (ACT) IMA101, using its proprietary ACTolog® approach. The IMA101 phase I trial is the first industry-sponsored trial using products consisting of autologous cytotoxic T lymphocytes targeting defined tumor antigens using Immatics’ novel and proprietary target warehouse.
A promising prophylactic vaccine candidate against Chikungunya fever will be tested from August on in a Phase II clinical study in Puerto Rico, a Chikungunya fever endemic area.
4SC AG announced the completion of its capital increase resolved on 12 June 2017 to continue to advance its drug development programs for resminostat, 4SC-202 and 4SC-208.
Sponsored by the National Institutes of Health, Themis Bioscience started a Phase II trial of its Chikungunya vaccine on a candidate in the U.S.
